Despite the early success of low-dose IL-2 trials in autoimmune diseases to date, there are two main limitations of this therapy as highlighted above: the short half-life of IL-2 requires frequent dosing that is low enough in individual and cumulative dosage to avoid Tconv activation, and off-target proliferative effects on other immune cells expressing IL-2 receptors. The gene discussed is IL2; the disease is autoimmune disease.